PT - JOURNAL ARTICLE AU - Ada J.S. Chan AU - Worrawat Engchuan AU - Miriam S. Reuter AU - Zhuozhi Wang AU - Bhooma Thiruvahindrapuram AU - Brett Trost AU - Thomas Nalpathamkalam AU - Carol Negrijn AU - Sylvia Lamoureux AU - Giovanna Pellecchia AU - Rohan Patel AU - Wilson W.L. Sung AU - Jeffrey R. MacDonald AU - Jennifer L. Howe AU - Jacob Vorstman AU - Neal Sondheimer AU - Nicole Takahashi AU - Judith H. Miles AU - Evdokia Anagnostou AU - Kristiina Tammimies AU - Mehdi Zarrei AU - Daniele Merico AU - Dimitri J. Stavropoulos AU - Ryan K.C. Yuen AU - Bridget A. Fernandez AU - Stephen W. Scherer TI - Genome-wide rare variant score associates with morphological subtypes of autism spectrum disorder AID - 10.1101/2021.10.20.21264950 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.20.21264950 4099 - http://medrxiv.org/content/early/2021/10/26/2021.10.20.21264950.short 4100 - http://medrxiv.org/content/early/2021/10/26/2021.10.20.21264950.full AB - Defining different genetic subtypes of autism spectrum disorder (ASD) can enable the prediction of developmental outcomes. Based on minor physical and major congenital anomalies, we categorized 325 Canadian children with ASD into dysmorphic and nondysmorphic subgroups. We developed a method for calculating a patient-level, genome-wide rare variant score (GRVS) from whole-genome sequencing (WGS) data. GRVS is a sum of the number of variants in morphology-associated coding and non-coding regions, weighted by their effect sizes. Probands with dysmorphic ASD had a significantly higher GRVS compared to those with nondysmorphic ASD (P= 0.027). Using the polygenic transmission disequilibrium test, we observed an over-transmission of ASD-associated common variants in nondysmorphic ASD probands (P= 2.9×10−3). These findings replicated using WGS data from 442 ASD probands with accompanying morphology data from the Simons Simplex Collection. Our results provide support for an alternative genomic classification of ASD subgroups using morphology data, which may inform intervention protocols.Competing Interest StatementS.W.S. is on the Scientific Advisory Committees of Deep Genomics, Population Bio and an Academic Consultant for the King Abdulaziz University.Funding StatementThis work was funded by Autism Speaks, Autism Speaks Canada, the University of Toronto McLaughlin Centre, the Canada Foundation for Innovation, the Canadian Institutes of Health Research (CIHR), Genome Canada/Ontario Genomics Institute, the Government of Ontario, Brain Canada, Ontario Brain Institute Province of Ontario Neurodevelopmental Disorders (POND), and The Hospital for Sick Children Foundation. A.J.S.C. was supported throughout this research by Ontario Graduate Scholarship from the Government of Ontario, Restracomp Research Fellowship from The Hospital of Sick Children, and Autism Research Training Award and Frederick Banting and Charles Best Scholarship from CIHR. S.W.S holds the Northbridge Chair in Paediatric Research at the Hospital for Sick Children.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Newfoundland Health Research Ethics Board (HREB# 2003.027) and SickKids Research Ethics Board (REB#0019980189).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccess to FASTQ data for samples in the discovery cohort that were consented for MSSNG can be obtained by completing the data access agreement: https://research.mss.ng. Access to FASTQ data for samples in the discovery cohort not consented for MSSNG, as well as VCF files for sequence-level variants for all samples in the discovery cohort are available at European Genome-Phenome Archive (pending EGA link and accession number. Submission in process.). Access to data for the replication cohort can be obtained by completing data access agreement (https://www.sfari.org/resource/sfari-base), as was done for this study. https://research.mss.ng/ https://www.sfari.org/resource/sfari-base